A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Atherosclerosis
- Sponsor
- Cordis Corporation
- Enrollment
- 394
- Locations
- 2
- Primary Endpoint
- Angiographic endpoint of in-stent late lumen loss as measured by QCA.
- Status
- Terminated
- Last Updated
- 13 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries. The study will evaluate the outcomes of a new drug-eluting stent compared to an approved drug-eluting stent.
While Cordis made a business decision to no longer pursue NEVO™ development and commercialization, the patients will be followed up as per protocol. This includes performing all protocol required follow-up visits and the collection and reporting of all safety information.
Detailed Description
Restenosis remains a frequent cause of late failure following successful coronary angioplasty occurring in an estimated 20-40% of procedures performed. Coronary stents provide mechanical scaffolding that helps reduce restenosis by limiting the extent of elastic recoil and late vascular remodeling. Despite improvements over balloon angioplasty alone, restenosis following coronary stenting procedures has been cited to occur in 20-40% of cases and is primarily a result of neointimal hyperplasia. Thus, stents which are capable of delivering drugs to limit neointimal hyperplasia, in addition to providing mechanical support at the area of the lesion, have been developed to further limit the extent of restenosis following coronary stenting. There are several pharmacologic agents approved for use with drug-eluting stents.Two drugs have been widely studied in controlled clinical trials and real-world patient populations, sirolimus and paclitaxel. This study will evaluate a new sirolimus-eluting cobalt chromium coronary stent system compared to an approved paclitaxel-eluting coronary stent system in the treatment of single de novo coronary lesions in native coronary arteries. Subjects meeting qualification will be randomized in a 1:1 fashion to treatment with the Conor sirolimus-eluting coronary stent or to treatment with an approved paclitaxel-eluting coronary stent. All subjects will undergo angiographic follow-up at six months and complete clinical follow-up for a period of five years.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •Eligible for percutaneous coronary intervention and coronary artery bypass graft surgery.
- •Diagnosis of stable or unstable angina or silent ischemia
- •Left ventricular ejection fraction \>30%
- •The subject requires treatment of a single de novo lesion in a native coronary artery.
- •Lesion to be treated is less than or equal to 28 mm in length in a vessel that is 2.5-3.5mm diameter.
- •The target lesion diameter stenosis is \>50% and \<100% by visual estimate.
- •The target lesion is a minimum of 10 mm distance from any previously treated segment of the target vessel.
- •The subject understands the study requirements, is willing to comply with all study procedures and has provided written informed consent.
Exclusion Criteria
- •The subject has undergone coronary revascularization to any vessel within 30 days.
- •The subject has undergone target vessel revascularization within 6 months.
- •Treatment of more than one qualifying lesion is required at the time of enrollment, or is planned within 30 days following enrollment.
- •The subject has known sensitivity to sirolimus, paclitaxel, the polymeric matrices, stainless steel or cobalt chromium.
- •There is planned treatment of the target lesion with any device other than the pre-dilatation balloon angioplasty catheter.
- •The subject had a myocardial infarction within 72 hours, or presents with CK elevation \> 2 times upper limit normal associated with elevated CK-MB.
- •The subject is in cardiogenic shock.
- •The subject had a cerebrovascular accident within the past 6 months.
- •The subject has acute or chronic renal dysfunction (defined as creatinine \>2.0 mg/dl).
- •The subject has a contraindication to aspirin or clopidogrel.
Outcomes
Primary Outcomes
Angiographic endpoint of in-stent late lumen loss as measured by QCA.
Time Frame: 6 months
Secondary Outcomes
- Target Lesion Failure defined as cardiac death that cannot be clearly attributed to a non-cardiac event or non-target vessel, target vessel related myocardial infarction or clinically driven target lesion revascularization.(hospital discharge, 30 days, 6 months and annually through five years.)
- Target Vessel Failure defined as any myocardial infarction or cardiac death that cannot be attributed to a non-target vessel or any target vessel revascularization.(Hospital discharge, 30 days, 6 months and annually through five years)
- Major Adverse Cardiac Events defined as an adjudicated composite of death, emergent coronary artery bypass graft surgery, target lesion revascularization, or new myocardial infarction.(Hospital discharge, 30 days, 6 months and annually through five years)
- Incidence of stent thrombosis(Hospital discharge, 30 days, 6 months and annually through five years)
- Incidence of target lesion revascularization and target vessel revascularization.(Hospital discharge, 30 days, 6 months and annually through five years)
- Device Success(Procedural)
- Lesion success(Procedural)
- Procedure Success(Hospital Discharge)
- Angiographic in-stent and in-segment binary restenosis.(6 months)
- In-stent minimum lumen diameter(6 months)
- Percent volume obstruction of the stent by intravascular ultrasound evaluation(6 months)
- Patient reported outcomes as measured by three standardized quality of life surveys.(Baseline, 30 days, 6 months and 12 months)